- Home
- ONT vs VSTM Comparison
ONT vs VSTM Comparison
Compare ONT & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ONT | VSTM |
|---|---|---|
| Founded | 2012 | 2010 |
| Country | United States | United States |
| Employees | 3500 | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 643.7M | 731.8M |
| IPO Year | 2020 | 2011 |
Fundamental Metrics
Financial Performance| Metric | ONT | VSTM |
|---|---|---|
| Price | $13.82 | $8.40 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 10 |
| Target Price | ★ $18.20 | $15.00 |
| AVG Volume (30 Days) | 648.9K | ★ 2.1M |
| Earning Date | 11-06-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 93.69 | 17.49 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $830,538,000.00 | $30,914,000.00 |
| Revenue This Year | N/A | $275.39 |
| Revenue Next Year | $8.17 | $55.47 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 19.26 | ★ 209.14 |
| 52 Week Low | $12.35 | $3.43 |
| 52 Week High | $23.32 | $10.82 |
Technical Indicators
Market Signals| Indicator | ONT | VSTM |
|---|---|---|
| Relative Strength Index (RSI) | 39.04 | 59.96 |
| Support Level | $12.68 | $7.29 |
| Resistance Level | $18.70 | $8.69 |
| Average True Range (ATR) | 1.15 | 0.48 |
| MACD | -0.09 | -0.00 |
| Stochastic Oscillator | 26.74 | 74.50 |
Price Performance
Historical ComparisonAbout ONT Onterris Inc. Common Stock
Onterris Inc is an environmental solutions company. The company provides environmental solutions to organizations addressing regulatory, operational, and environmental challenges. Its services include the application of scientific, engineering, and data-driven approaches to support risk management, compliance, and environmental protection, including air, water, and soil.
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.